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Abstract: The probiotic Bifidus BB536 (BB536), which contains Bifidobacterium longum, has been shown
to have enhanced probiotic effects when given together with a standardized extract of cultured Lentinula
edodes mycelia (AHCC®, Amino Up Co. Ltd., Sapporo, Japan). BB536 and AHCC® may modulate T
cell and dendritic cell (DC) phenotypes, and cytokine profiles to favour anti-inflammatory responses
following antibiotic ingestion. We tested the hypothesis that orally administered BB536 and/or
AHCC®, results in modulation of immune effector cells with polarisation towards anti-inflammatory
responses following antibiotic usage. Forty healthy male volunteers divided into 4 equal groups were
randomised to receive either placebo, BB536, AHCC® or a combination for 12 days in a double-blind
manner. After 7 days volunteers also received 250 mg azithromycin for 5 days. Cytokine profiles
from purified CD3+ T cells stimulated with PDB-ionomycin were assessed. CD4+ CD25+ forkhead
box P3 (Foxp3) expression and peripheral blood DC subsets were assessed prior to treatment and
subsequently at 7 and 13 days. There was no difference in cytokine secretion from stimulated CD3+ T
cells between treatment groups. Compared with baseline, Foxp3 expression (0.45 ± 0.1 vs. 1.3 ± 0.4;
p = 0.002) and interferon-gamma/interleukin-4 (IFN-γ/IL-4) ratios were increased post-treatment in
volunteers receiving BB536 (p = 0.031), although differences between groups were not significant.
For volunteers receiving combination BB536 and AHCC®, there was an increase in myeloid dendritic
cells (mDC) compared with plasmacytoid DC (pDC) counts (80% vs. 61%; p = 0.006) at post treatment
time points. mDC2 phenotypes were more prevalent, compared with baseline, following combination
treatment (0.16% vs. 0.05%; p = 0.002). Oral intake of AHCC® and BB536 may modulate T regulatory
and DC phenotypes to favour anti-inflammatory responses following antibiotic usage.
Keywords: probiotics; prebiotics; synbiotics; antibiotics; dendritic cells; immunity; Bifidobacterium
longum; AHCC®
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1. Introduction
Administration of antibiotics, whilst valuable for the treatment of bacterial infections, is associated
with adverse effects that include disruption of gastrointestinal ecology. This may allow potentially
harmful bacteria to proliferate, cause gastrointestinal symptoms [1,2] and increase the rates of antibiotic
resistance [3]. Strategies to reduce these effects include the use of probiotics.
Probiotics are characterised by their ability to survive the harsh acidic environment of the stomach
and subsequent transit through the gut where they are known to impart favourable effects for the host,
especially in conditions with significant intestinal dysbiosis [4,5]. Evidence for these effects comes
from randomised studies suggesting that probiotics are useful along with rehydration therapy for the
treatment of infectious diarrhoea in children [6–8], traveller’s diarrhoea [9] and antibiotic-associated
diarrhoea in both children [10,11] and adults [12–14]. Prebiotics, usually oligosaccharides or dietary
carbohydrates, can act as nutrients for probiotics and may enhance their useful effects when
administered together. When incorporated in a single preparation they are known as synbiotics [15].
Recent attention has focused on the capacity of probiotics to modify human immune cell responses
and reduce the severity of gastrointestinal infections by bacterial pathogens [16–18]. Modulation of
gut immunity in this way can alter inflammatory or suppressive immunity and is a key factor for
the tolerance or intolerance to antigenic molecules encountered by the mucosa. Fundamental to this
process are complex interactions between the mucosal immune apparatus including dendritic cells
(DCs), regulatory T (Treg) cells and intestinal bacteria [17]. A proposed mechanism of host immune
cell modulation by probiotic bacteria involves a shift in the balance of mucosal responses towards
anti-inflammatory cytokine production [19,20]. This effect has been demonstrated for several strains of
Bifidobacterium which promote the production of the anti-inflammatory cytokine, interleukin (IL) -10 by
CD4+ T cells isolated from mouse colon epithelium following oral administration of the probiotic [21].
Further evidence to support the anti-inflammatory properties of probiotics in the gut is provided by
in vitro experiments showing an attenuation of lipopolysaccharide (LPS) stimulated inflammatory
cytokine production by epithelial cells following pre-incubation with Lactobacillus reuteri [22].
DCs are considered the most specialised antigen presenting cells (APCs) within the gut and
there is evidence that immunological functions of DCs can be modulated following exposure to
probiotics [23]. Co-culture of Lactobacilli gasseri, johnsonii and reuteri with human myeloid dendritic cells
(mDCs) resulted in secretion of IL-12 and IL-18 with skewing of T lymphocyte polarisation towards a
T helper (Th) 1 class response [24]. Other studies have demonstrated an induction of the regulatory
protein, forkhead box P3 (FoxP3+) T cells and the production of anti-inflammatory cytokines by DCs
in response to exposure to probiotics [25]. FoxP3+ T cells are key immune suppressive cells inhibiting
the activity of cell mediated immunity. They minimise the function of both CD8+ T cells (generation
of antigen-specific cytotoxic T lymphocytes) and CD4+ T cells (production of Th1/Th2 cytokines).
They suppress the initiation of T cell interaction with antigens (bacterial/viral) and help to restrict the
prominence of tissue immune responses, thereby preventing uncontrolled damage and restoration
of immune homeostasis. By inhibiting IL-12 and interferon-gamma (IFN-γ) production they prevent
the activation of the innate immune natural killer (NK) cells. Thus, potentially they could be both
detrimental and beneficial to the host’s immune defences depending on the pathophysiological state of
the gut micro-environment of the host. mDcs in this study were activated and mature, thus increasing
their ability to present antigens (bacterial, viral) to CD8+ and CD4+ T cells and enhancing their effector
functions. In addition, exposure to probiotic bacteria has been shown to affect DC co-stimulatory
molecule expression [26].
Prebiotics are oligosaccharide molecules known to enhance the effects of probiotics. In the rat
model, co-administration of a standardized extract of cultured Lentinula edodes mycelia (AHCC®) with
the probiotic Bifidobacterium longum BB536 was shown to reduce enzymatic markers of colitis and
it is proposed that AHCC® may act synergistically to promote the immunomodulatory properties
of Bifidus BB536 although these effects have yet to be studied in human subjects. In the rat model,
co-administration of AHCC® with the probiotic Bifidobacterium longum (Bifidus BB536) was shown to
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reduce enzymatic markers of colitis and it is proposed that AHCC® may act synergistically to promote
the immunomodulatory properties of Bifidus BB536 although these effects have yet to be studied in
human subjects.
Oral immunomodulation is a means for modifying the systemic immune system through an effect
on the gut. It is based on a process in which the gut immune system reacts to orally administered antigens
to produce proteins that generate systemic adaptive responses [27]. Responses to nutrients, pathogens,
commensals, or orally administered antigens to which the gut mucosa is exposed, are dependent on
the interaction with mucosal immune cells and lead to subsequent systemic responses [28]. For this
reason, the study of blood immune parameters following oral probiotic administration can be reflective
of changes that originate at the gut mucosal level.
This study tested the hypothesis that the oral administration of probiotics and/or prebiotics in
healthy volunteers alters blood immune cell phenotypes and aimed to study the effects of orally
administered probiotics (Bifidus BB536 (BB536) which contains Bifidobacterium longum (Morinaga Milk
Industry Co. Ltd., Tokyo, Japan) and/or a standardized extract of cultured Lentinula edodes mycelia
(AHCC®, Amino Up Co. Ltd., Sapporo, Japan), on T cell and DC phenotype and function. An antibiotic
treatment phase was included to determine if the immunomodulatory effects of probiotic and prebiotic
administration persist following oral antibiotic ingestion.
2. Methods
2.1. Study Design
In this double-blind, randomised study, four different treatments were administered for a total
of 12 days each. After 7 days of baseline treatment, all groups were prescribed a broad-spectrum
antibiotic (azithromycin 250 mg once daily) for a total of 5 days (Table 1).
Table 1. Summary of healthy volunteer randomisation and treatment regimens.
Group Treatment Length Intervention
1 (n = 10) Placebo arm 7 days Placebo prebiotic and placebo probiotic
5 days Azithromycin and placebo prebiotic and placebo probiotic
2 (n = 10) Probiotic arm 7 days Placebo prebiotic and BB536
5 days Azithromycin, placebo prebiotic and BB536
3 (n = 10) Prebiotic arm 7 days AHCC
® and placebo probiotic
5 days Azithromycin, AHCC® and placebo probiotic
4 (n = 10) Synbiotic arm 7 days AHCC
® and BB536
5 days Azithromycin, AHCC® and BB536
AHCC®, a standardized extract of cultured Lenitula edodes mycelia (Amino Up Co. Ltd., Sapporo, Japan) 300 mg in
a gelatin capsule. Bifidobacterium longum (BB536, Morinaga Milk Industry Co. Ltd., Tokyo, Japan) 1.25 × 1010 CFU/g
in a gelatin capsule. Placebos: Corn starch 200 mg in a gelatin capsule identical to AHCC® and BB536 capsules.
Antibiotic: Azithromycin dehydrate (Zithromax, Pfizer Inc., New York, NY, USA) 250 mg tablet given once daily.
2.2. Inclusion and Exclusion Criteria
Volunteers were eligible to participate if they were male, aged between 18–55 years and able to
give informed consent. Volunteers were excluded from the study if they had been diagnosed with
diabetes mellitus, any immune disorder or were currently under medical investigation. Exclusions also
included steroid medication, smoking/substance abuse, allergy to azithromycin or regular medications,
probiotics or nutritional supplements.
2.3. Interventions
Volunteers allocated to the probiotic arm of the study received capsules of BB536, containing
1.25 × 1010 CFU/g of the probiotic bacteria, Bifidobacterium longum. Those volunteers allocated to the
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prebiotic arm received capsules containing AHCC®. This extract of cultured Lenitula edodes mycelia
contains polysaccharides, amino acids, and minerals that are utilized by Bifidobacterium spp. [29].
Volunteers in the synbiotic arm received both BB536 and AHCC® capsules. Placebos consisted of corn
starch within a gelatin capsule at a dose of 200 mg and were identical in appearance to BB536 and
AHCC® capsules. Azithromycin (Zithromax, Pfizer Inc., New York, NY, USA), given to all groups
after 7 days, consisted of a 250 mg tablet administered in a once daily dose. It has broad spectrum
activity against a wide range of bacteria which includes the Bifidobacterium spp. [30].
2.4. Blood Sampling and Immunological Assays
Healthy volunteers provided a total of 3 blood samples: prior to commencing the study (time
point 1), after 7 days of treatment (time point 2) and a final sample at the completion of treatment
(day 13, time point 3). Peripheral blood mononuclear cells (PBMCs) were harvested and stored in
preparation for immunological assays. A flow diagram summarising the immunological assays is given
in Figure 1. A full description of the assay methodology is provided in the Supplementary Materials.
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2.5. Randomisation, Blinding and Allocation Concealment
Participants were allocated with equal probability to one of the four treatment groups.
The randomisation was based on a computer-generated code using random blocks of varying size
held on a secure server within the Nottingham Clinical Trials Unit (CTU). Access to the sequence
was confined to the CTU data manager. Investigators had access to the treatment allocation for each
participant by means of a remote, internet-based randomisation system. The sequence of treatment
allocations was concealed until interventions had been assigned and recruitment, data collection, and all
other trial-related assessments were complete. Both the subjects and the investigators were blinded to
group allocations. The randomisation code was broken only after completion of the statistical analysis.
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2.6. Sample Size Calculation
As this was a pilot study, the effect size of the treatments was not known. It was estimated at a
sample size of 40 (10 in each) group would help discern whether meaningful differences between the
groups could be detected.
2.7. Statistical Analysis
Statistical analysis was performed with GraphPad Prism version 8.0.2 for Mac, (GraphPad
Software, San Diego, CA, USA, www.graphpad.com) using a repeated measures ANOVA design.
Parametric data were analysed with the Student t test and non-parametric data with the Wilcoxon test
for matched pairs. Differences were considered significant at p < 0.05.
2.8. Ethics and Trial Registration
This study was granted approval by the University of Nottingham Medical School Ethics
Committee and was registered at http://www.clinicaltrials.gov (NCT01201577).
3. Results
3.1. Volunteer Baseline Characteristics
There were no significant differences between groups with respect to baseline characteristics of
the 40 volunteers studied (Table 2).
Table 2. Baseline characteristics of volunteers in the 4 treatment groups. Values presented are mean
(SEM).
Normal Range Placebo BB536 AHCC® BB536/AHCC®
Age (yr) 20.3 (0.2) 21.1 (0.2) 20.9 (0.3) 22.5 (0.3)
Height (m) 1.82 (0.02) 1.77 (0.02) 1.78 (0.02) 1.80 (0.02)
Weight (kg) 63.1 (0.3) 65.4 (0.2) 77.2 (0.3) 68.9 (0.2)
Haemoglobin (g/dL) 130–180 g/L 14.1 (0.2) 15.0 (0.2) 13.9 (0.2) 14.8 (0.2)
White cell count (×109/L) 4.0–11.0 × 109/L 6.9 (0.7) 8.7 (0.5) 6.8 (0.7) 8.1 (0.5)
Platelet count (×109/L) 140–400 × 109/L 302 (8) 323 (7) 298 (7) 335 (8)
Serum bilirubin (µmol/L) <21 µmol/L 10 (2) 8 (1) 14 (2) 6 (1)
Serum alanine amino transferase (IU/L) 2–53 iu/L 25 (4) 27 (3) 30 (4) 19 (3)
Serum alkaline phosphatase (IU/L) 30–130 iu/L 58 (5) 77 (6) 63 (5) 71 (5)
Serum albumin (g/L) 35–50 g/L 38 (0.4) 39 (0.4) 36 (0.4) 41 (0.4)
Serum sodium (mmol/L) 133–146mmol/L 134 (0.5) 134 (0.4) 135 (0.4) 133 (0.5)
Serum potassium (mmol/L) 3.3–5.3mmol/L 4.8 (0.2) 4.2 (0.2) 4.2 (0.2) 4.5 (0.2)
Blood urea (mmol/L) 2.5–7.8 mmol/L 5.2 (0.2) 4.5(0.2) 3.6 (0.2) 4.3 (0.2)
Serum creatinine (mmol/L) 60–120µmol/L 98 (3) 77 (3) 64 (2) 74 (3)
Serum C-reactive protein (mg/L) 0–10 mg/L 8.1 (0.5) 8 (0.4) 7 (0.4) 5 (0.4)
There were no statistically significant differences in baseline parameters between the groups (p > 0.05).
3.2. Effect of Prebiotic and Probiotic or Antibiotic on Serum Inflammatory Markers
White cell count and C-reactive protein (CRP) concentrations were below 11 × 109/L and 10 mg/L
respectively at all time points and there were no statistically significant differences between the
four groups.
3.3. In Vitro Cytokine Secretion by CD3+ T Cells in Response to PDB-Ionomycin
Following in vitro stimulation with phorbol 12,13-dibutyrate (PDB)-ionomycin there was an
increase in cytokine secretion from CD3+ T cells compared with untreated cells or treatment
with dimethyl sulphoxide (DMSO) measured with both cytometric bead array and enzyme-linked
immunosorbent sandwich assay. This included IFN-γ (859.5 vs. 70.2 pg/mL, p = 0.014) and IL-2 (4418.5
vs. 45.7 pg/mL, p = 0.024) (Th1 class) as well as IL-4 (9.96 vs. 2.67 pg/mL, p = 0.01), IL-5 (18.78 vs.
8.14 pg/mL, p = 0.034), IL-6 (68.88 vs. 13.08 pg/mL, p = 0.041) and IL-10 (11.11 vs. 6.18 pg/mL, p = 0.029)
(Th2 class) This effect was seen for cells in pretreatment and both posttreatment phases and indicates
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an intact response to stimulation. However, there were no significant differences in the magnitude of
cytokine secretion between treatment groups (p > 0.05 for all comparisons).
3.4. Th1:Th2 Class Cytokine Ratios
In vitro phorbol 12,13-dibutyrate (PDB)-ionomycin stimulated cytokine release by CD3+ T cells
categorized according to class demonstrated no shift except when examining the ratio of IFN-γ to
IL-4. Following treatment with BB536, there was a significant increase in the ratio of IFN-γ to IL-4
(time point 1 vs. time point 2, p = 0.031). However, this ratio returned to baseline levels following the
administration of antibiotic (time point 2 vs. time point 3, p = 0.047). All other calculated ratios did not
demonstrate a shift in Th1 and Th2 class cytokines (p > 0.05 for all comparisons).
3.5. Foxp3 Expression as a Marker of T Regulatory CELL (Treg) Activity
Assay of CD4+CD25+ Foxp3+ Tregs by flow cytometry demonstrated a level of <3% of peripheral
blood mononuclear cells (PBMCs). Volunteers receiving BB536 demonstrated a significant increase in
the level of Foxp3+ Tregs (0.45% vs. 1.36%, p = 0.046) over the course of treatment. Volunteers receiving
AHCC® demonstrated a significant increase in Foxp3+ Tregs (0.49% vs. 0.70%, p = 0.0059) in the first
week of treatment only but the expression of Foxp3+ Tregs returned to pretreatment values at the end
of the study. There was no difference in Foxp3+ Treg expression in volunteers who received either
placebo or a combination of BB536 and AHCC® (Figure 2).
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Figure 2. CD4+ CD25+ Foxp3+ cells (Tregs) as determined by cytometric bead array. X-axis represents 
different sampling time points during the study. Values represent mean (SEM). Significance 
calculated using the Student t test (paired). BB536: Bifidobacterium longum; AHCC®: a standardized 
extract of cultured Lentinula edodes mycelia; *: p < 0.05; **: p < 0.01. Time points: 1—pretreatment, 2—
after 7 days of placebo (a)/BB536 (b)/AHCC® (c)/both (d), 3—after an additional 5 days of placebo 
(a)/BB536 (b)/AHCC® (c)/both (d) + azithromycin (day 13). 
CD25+ Foxp3+ cells (Tregs) as determined by cytometric bead array. - i
ff t sampling time points during the s udy. Values repr ent m an (SEM). Significance calcul ted
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cultured Lentinula edodes mycelia; *: p < 0.05; **: p < 0.01. Time points: 1—pretreatment, 2—after 7
days of placebo (a)/BB536 (b)/AHCC® (c)/both (d), 3—after an dditio al 5 days of placebo (a)/BB536
(b)/AHCC® (c)/both (d) + azithromycin (day 13).
3.6. Plasmacytoid (pDC) and Myeloid (mDC) Dendritic Cells
Peripheral blood revealed higher cell counts (%) of mDCs compared with pDCs in all treatment
groups (Figure 3A i–iv). Between treatment groups, there were no significant differences in the counts
of DC subsets except for volunteers receiving the BB536/AHCC® combination. In this group, the
proportion of mDCs as a percentage of the total number of DCs was significantly higher at both time
points following the commencement of treatment [74.50 (68.25–86.50), p = 0.0078 and 80.50 (75.25–84.50),
p = 0.0059 respectively, Figure 3A iv].
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No significant changes in the relative proportions of mDC1 to mDC2 occurred in the treatment
groups except for volunteers who received the BB536/AHCC® combination (Figure 3B). In this group,
there was a significant increase in the mDC2 subset as a percentage of total mDCs at both post-treatment
time points [0.149 (0.140–0.174), p = 0.002 and 0.138 (0.122–0.162) p = 0.002, Figure 3B iv].
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3.7. Co-Stimulatory Molecule Expression in DC Subsets
There were no differences between CD40 and CD86 surface expression on pDCs and mDCs
between treatment groups (p > 0.05 for all comparisons). (Figure 4A).
Nutrients 2019, 11, x FOR PEER REVIEW  8 of 14 
No significant changes in the relative proportions of mDC1 to mDC2 occurred in the treatment 
groups except for volunteers who received the BB536/AHCC® combination (Figure 3B). In this group, 
there was a significant increase in the mDC2 subset as a percentage of total mDCs at both post-
treatment time points [0.149 (0.140–0.174), p = 0.002 and 0.138 (0.122–0.162) p = 0.002, Figure 3B iv]. 
. .       
   iffere c s et     s rf  i      
 t t r s (p >       
 
Figure 4. (A) Cell surface co-stimulatory marker CD40 expression on DC subsets as percentage of total 
DCs. (B) Cell surface co-stimulatory marker CD86 expression on DC subsets as percentage of total 
DCs. Values represent mean (SEM). Significance calculated using the Student t test (paired). BB536: 
Bifidobacterium longum; AHCC®: a standardized extract of cultured Lentinula edodes mycelia; *: p < 0.05. 
Time points: 1—pretreatment, 2—after 7 days of placebo (i)/BB536 (ii)/AHCC® (iii)/both (iv), 3 – after 
an additional 5 days of placebo (i)/BB536 (ii)/AHCC® (iii)/both (iv) + azithromycin (day 13). 
. ( ) ll s f - ti l t i t t f t t l
. t t l
fi t ( i .
ifidobacterium longum; AHCC® ti la edodes ycelia; *: .
i e oints: treat e t, 2 after 7 days of placebo (i)/BB536 (i )/AHCC® —
iti l f l (i)/ 536 (i )/ CC® it r i ( .
However, there was a significant increase in both CD40 (time point 1 vs. time point 2: 18.5% vs.
30.5%, p = 0.029 and time point 1 vs. time point 3: 18.5% vs. 36.5%, p = 0.027, Figure 4A iv) and CD86
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(time point 1 vs. time point 2: 24% vs. 38%, p = 0.034 and time point 1 vs. time point 3: 24% vs. 40.5%,
p = 0.029, Figure 4B iv) surface marker expression in mDC2 subset for volunteers receiving the BB536
and AHCC® combination.
4. Discussion
In this study of healthy volunteers, we have demonstrated an increase in the percentage of mDCs
following the oral administration of a combination of BB536 and AHCC®. This is in contrast to the
percentage of pDCs. Treatment with this combination also led to a shift towards the mDC2 subset with
greater expression of the co-stimulatory molecules CD40 and CD86, suggesting DC activation and
maturation, albeit mDC2 is the less common subset.
On the other hand, treatment with either BB536 or AHCC® did not lead to any differences in
PDB-ionomycin stimulated cytokine release from CD3+ T cells. Foxp3+ Tregs, however, were increased
with either BB536 or AHCC® but not in combination.
The results of the present study suggest differential expansion and activation of DC subsets in
response to the oral administration of a synbiotic preparation. This effect was observed to persist even
after the administration of azithromycin 250 mg daily for 5 days. In the gut, both mDCs and pDCs are
responsible for presenting microbial and dietary antigens to the adaptive immune system, thereby
influencing polarisation of the adaptive response via cytokine and metabolite production [31,32].
The results of the present study indicate that oral ingestion of synbiotic preparations may modulate
DC subgroups and promote expansion of the less common mDC2 subset. This in turn would favour a
Th2 type of cytokine response and suppression of inflammatory cytokine secretion. This, however,
was not borne out by our observations for stimulated T lymphocyte helper responses which remained
similar for all treatment groups.
Previous work has indicated that probiotic bacteria can influence cytokine release from different
classes of immune cells. However, much of this work has been conducted in animals or the in vitro
setting mainly examining effects of lactic acid-producing bacteria [33–37]. When examining specifically
the role of T lymphocytes, most studies have investigated the direct effects of co-culturing probiotic
bacteria with PBMCs [38–41]. A further study examined cytokine production by human T lymphocytes
following co-culture with various strains of bacteria including Bifidobacterium lactis, Lactobacillus
acidophilus, Lactobacillus plantarum and Escherichia coli [39]. They were able to demonstrate increased
production of IL-10, IL-17, IFN-γ and IL-13, although there were no significant differences in cytokine
production between strains [39]. IL-10 is known to inhibit Th1 proliferation and suppress IFN-γ and
IL-2 release. A possible mechanism for probiotic action could involve the induction of IL-10 release
from T lymphocytes and this has been shown for colonic lamina propria and Peyer’s patch-derived
T lymphocytes by Bifidobacterium strains in mice [21,42]. In the present study, concentrations of
IL-10 following stimulation of T lymphocytes with PDB-ionomycin were not significantly elevated
above those obtained with controls. There were also no significant differences in IL-10 concentrations
between groups receiving placebo, BB536, AHCC® or combination. A healthy human volunteer
study investigating cytokine release following treatment for 8 weeks of Bifidobacterium infantis and
stimulation of PBMCs found increased IL-10 production but no difference in the production of IL-2,
IL-12p70, tumour necrosis factor-alpha (TNF-α) and IFN-γ [25]. No studies have examined the
optimum treatment duration required to observe changes in immune cell cytokine production. It is,
therefore, possible that the treatment duration in the present study may have been insufficient to
produce overt changes in cytokine release.
In the present study, volunteers receiving BB536 demonstrated a significant increase in the
percentage of CD4+ lymphocytes expressing Foxp3 following the total treatment period, an effect not
observed for volunteers receiving placebo, AHCC® or combination treatment. Probiotic bacteria have
been shown in several studies to increase the expression of Foxp3. Cells expressing Foxp3 are known
to play an important suppressive role in the immune system by directly modulating the expansion
and function of T-cells. Again, these experiments have mainly utilised probiotic strains co-cultured
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with PBMCs in vitro or have been conducted in murine studies [21,37,39,41]. On the whole, these
studies indicate that probiotic bacteria and Lactobacillus spp. in particular induce the expression of
Foxp3 from PBMCs and, in addition, induce the expression of immunosuppressive cytokines, such
as IL-10 [21,39]. A study involving healthy human volunteers treated with Bifidobacterium infantis
for 8 weeks demonstrated a significant increase in the percentage of CD4+ CD25high T cells that
also expressed Foxp3 [25]. The investigators subsequently co-cultured Bifidobacterium infantis with
monocyte-derived DCs which were shown to increase expression of Foxp3 and production of IL-10.
They were also able to demonstrate differential mechanisms for Foxp3 induction by DCs, with an
mDC pathway requiring TLR-2, DC-SIGN and retinoic acid and a pDC pathway requiring indolamine
2,3-dioxygenase (IDO) [25]. In the present study, an increase in CD4+ lymphocytes expressing Foxp3
following treatment with BB536 was not observed with combination treatment of BB536 and AHCC®.
Oligosaccharides such as AHCC® are known to promote proliferation of Bifidobacterium although
it remains unclear how long this positive interaction lasts or to what degree intestinal colonisation
proceeds as a result. One could speculate that the effects on Tregs following combination treatment
are population dependent and an increase in BB536 intestinal population beyond a specific threshold
could result in attenuation of this effect. It is also possible that by favouring the proliferation of BB536,
an adhesive or colonising phenotype might be prevented when a preferred dietary substrate is present.
This may account for the lack effect seen when administering the two components together.
The polarisation of host immune responses and the effects on DCs, T helper and regulatory
cells are likely to be central to the observed effects of probiotic administration when given for
therapy in gastrointestinal infections. Mechanisms for this seem centred on the induction of Tregs,
modulation of cytokine expression or differential activation of DC subsets. This has been specifically
demonstrated for Lactobacillus spp. with a differential induction of IL-12 and TNFα [43]. Others have
shown augmented expression of the DC maturation markers, MHC II and CD86 [44]. There is
evidence for polarised cytokine DC subset activation in response to helminth exposure with a
predominance for Th2 cytokine expression for activated cells [45]. Similarly, Polysaccharide A (PSA),
the archetypical immunomodulatory molecule of the gut commensal Bacteroides fragilis, induces Tregs
to secrete the anti-inflammatory cytokine IL-10 and Bifidobacterium bifidum has been shown to be
an effective inducer of Tregs in response to dietary antigens [46,47]. Results from recent human
studies indicate similar anti-inflammatory mechanisms in regard to cytokine expression and effector
cell phenotypes. Analysis of LPS stimulated PBMCs obtained from human volunteers following
ingestion of Bifidobacterium animalis subsp. lactis BB-12 demonstrated lower TNF-α secretion and
reduced expression of TLR-2 on CD14+HLA-DR+ cells [48]. A randomised human study of patients
with metabolic syndrome demonstrated a reduction in plasma concentrations of both IL-6 and TNF-α
following 45 days of oral treatment with fermented milk containing Bifidobacterium lactis [49]. In this
way probiotic bacteria can enhance the mucosal immune system to control responses to luminal antigens
and limit mucosal inflammation which is a central pathogenic feature of gastrointestinal infections.
There are a number of limitations of this study which should be considered. Firstly, this study
was conducted with healthy volunteers, in whom responses both immunological and physiological are
likely to be different from those with illness. It could be argued that the observed changes in immune
cell phenotype and function may not be directly applicable to clinical settings of physiological stress,
such as surgical trauma or sepsis. However, the intention of this study was to observe the effects
of probiotic and prebiotic ingestion in health to determine immunological effects in the absence of
other confounding factors such as sepsis, trauma or systemic inflammation. Differential expansion
of DC subsets persisted even after antibiotic treatment. There is some evidence in the mouse model
that pasteurized probiotic bacteria can still affect metabolic processes and it may have been of value
in the present study to include a heat-inactivated control to determine if the immunomodulatory
properties are seen with inactivated bacteria [50]. It could also be argued that the study did not
incorporate an objective biological measure of treatment compliance. Collectively, volunteers tolerated
the treatments well and there were no significant adverse effects associated with any of the treatment
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groups. In addition, at each sampling time point volunteers were asked to bring the medications
prescribed and remaining capsules were counted. Nevertheless, the risk of non-compliance was
significant and remains a possible limitation of the study. In an effort to limit the effects of cyclical
variation of endogenous steroid hormones on cellular immunity we recruited only male subjects to
participate in this study. It is acknowledged that this may limit the wider extrapolation of these results.
Finally, whilst this study has demonstrated immunomodulation following synbiotic ingestion, the
pathways responsible for immunomodulation are clearly complex and warrant further investigation to
elucidate precise mechanisms.
To summarise, the results obtained in this study demonstrate that in healthy individuals, oral
supplementation with BB536 and AHCC® or combinations had varying effects on T cells and dendritic
cell populations and the expression of surface markers. The administration of either BB536 or AHCC®
was associated with increased expression of Foxp3 by T cells. The synbiotic combination of BB536
and AHCC® was associated with a preferential increase in mDCs, and in particular the mDC2 subset.
In addition, combination treatment was associated with increased expression of activation markers
CD40 and CD86. These immunomodulatory effects warrant further investigation to uncover the
mechanisms by which probiotics/prebiotics may exert any beneficial effects.
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